J. Kiladjian, C. Harrison, R. Mesa, H. Al-Ali, J. Mascarenhas, Fabián Sanabria, Julie Vienne Bürki, B. Bengoudifa, F. Passamonti
{"title":"MPN-346独立性:纳入III期试验,研究Luspatercept与安慰剂在需要红细胞输注的JAK2抑制剂(JAK2i)治疗的骨髓纤维化患者中的疗效和安全性","authors":"J. Kiladjian, C. Harrison, R. Mesa, H. Al-Ali, J. Mascarenhas, Fabián Sanabria, Julie Vienne Bürki, B. Bengoudifa, F. Passamonti","doi":"10.1016/s2152-2650(23)01234-x","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10370,"journal":{"name":"Clinical Lymphoma Myeloma and Leukemia","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)\",\"authors\":\"J. Kiladjian, C. Harrison, R. Mesa, H. Al-Ali, J. Mascarenhas, Fabián Sanabria, Julie Vienne Bürki, B. Bengoudifa, F. Passamonti\",\"doi\":\"10.1016/s2152-2650(23)01234-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10370,\"journal\":{\"name\":\"Clinical Lymphoma Myeloma and Leukemia\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma Myeloma and Leukemia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s2152-2650(23)01234-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma Myeloma and Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s2152-2650(23)01234-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)